Format

Send to

Choose Destination
Hum Reprod. 2018 Sep 1;33(9):1767-1776. doi: 10.1093/humrep/dey262.

Preimplantation genetic testing for aneuploidy by microarray analysis of polar bodies in advanced maternal age: a randomized clinical trial.

Author information

1
Centre for Reproductive Medicine, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, Belgium.
2
Research Group Reproduction and Genetics, Vrije Universiteit Brussel, Laarbeeklaan 103, Brussels, Belgium.
3
Centre for Medical Genetics, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, Brussels, Belgium.
4
Academisch Medisch Centrum, Meibergdreef 9, AZ Amsterdam, The Netherlands.
5
The European Society of Human Reproduction and Embryology, Meerstraat 60, Grimbergen, Belgium.
6
Shaare-Zedek Medical Center, The Hebrew University School of Medicine, 2 Bayit Street, Jerusalem, Israël.
7
Centre for Medical Genetics, UZ Brussel, Laarbeeklaan, Belgium.
8
Hospital Univeritario Dexeus, Department of Obstetrics, Gynaecolgy and Reproduction, Gran Via de Carles III 71-74, Barcelona, Spain.
9
SISMER, Reproductive Medicine Unit, Via Mazzini 12, Bologna, Italy.
10
University Hospital of Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee 160, Lübeck, Germany.
11
Department of Medical Genetics, National and Kapodistrian University of Athens, 'Aghia Sophia' Children's Hospital, 75 Mikras Asias str., Goudi, Athens, Greece.
12
Genesis Athens Clinic, Reproductive Medicine Unit, Papanikoli 14-16, Chalandri, Athens, Greece.
13
Department of Gynecological Endocrinology and Reproductive Medicine, University Hospital Bonn, Sigmund-Freud-Str. 25, Bonn, Germany.
14
Women's Hospital, Christian-Albrechts-University, Christian-Albrechts-Platz 4, Kiel, Germany.
15
Gyn-medicum, Centre for Reproductive Medicine, Waldweg 5, 37073 Goettingen, Germany.
16
Department of Genetics and Cell Biology, Maastricht University Medical Center, P. Debyelaan 25, Maastricht, The Netherlands.

Abstract

STUDY QUESTION:

Does preimplantation genetic testing for aneuploidy (PGT-A) by comprehensive chromosome screening (CCS) of the first and second polar body to select embryos for transfer increase the likelihood of a live birth within 1 year in advanced maternal age women aged 36-40 years planning an ICSI cycle, compared to ICSI without chromosome analysis?

SUMMARY ANSWER:

PGT-A by CCS in the first and second polar body to select euploid embryos for transfer does not substantially increase the live birth rate in women aged 36-40 years.

WHAT IS KNOWN ALREADY:

PGT-A has been used widely to select embryos for transfer in ICSI treatment, with the aim of improving treatment effectiveness. Whether PGT-A improves ICSI outcomes and is beneficial to the patients has remained controversial.

STUDY DESIGN, SIZE, DURATION:

This is a multinational, multicentre, pragmatic, randomized clinical trial with intention-to-treat analysis. Of 396 women enroled between June 2012 and December 2016, 205 were allocated to CCS of the first and second polar body (study group) as part of their ICSI treatment cycle and 191 were allocated to ICSI treatment without chromosome screening (control group). Block randomization was performed stratified for centre and age group. Participants and clinicians were blinded at the time of enrolment until the day after intervention.

PARTICIPANTS/MATERIALS, SETTING, METHODS:

Infertile couples in which the female partner was 36-40 years old and who were scheduled to undergo ICSI treatment were eligible. In those assigned to PGT-A, array comparative genomic hybridization (aCGH) analysis of the first and second polar bodies of the fertilized oocytes was performed using the 24sure array of Illumina. If in the first treatment cycle all oocytes were aneuploid, a second treatment with PB array CGH was offered. Participants in the control arm were planned for ICSI without PGT-A. Main exclusion criteria were three or more previous unsuccessful IVF or ICSI cycles, three or more clinical miscarriages, poor response or low ovarian reserve. The primary outcome was the cumulative live birth rate after fresh or frozen embryo transfer recorded over 1 year after the start of the intervention.

MAIN RESULTS AND THE ROLE OF CHANCE:

Of the 205 participants in the chromosome screening group, 50 (24%) had a live birth with intervention within 1 year, compared to 45 of the 191 in the group without intervention (24%), a difference of 0.83% (95% CI: -7.60 to 9.18%). There were significantly fewer participants in the chromosome screening group with a transfer (relative risk (RR) = 0.81; 95% CI: 0.74-0.89) and fewer with a miscarriage (RR = 0.48; 95% CI: 0.26-0.90).

LIMITATIONS, REASONS FOR CAUTION:

The targeted sample size was not reached because of suboptimal recruitment; however, the included sample allowed a 90% power to detect the targeted increase. Cumulative outcome data were limited to 1 year. Only 11 patients out of 32 with exclusively aneuploid results underwent a second treatment cycle in the chromosome screening group.

WIDER IMPLICATIONS OF THE FINDINGS:

The observation that the similarity in birth rates was achieved with fewer transfers, less cryopreservation and fewer miscarriages points to a clinical benefit of PGT-A, and this form of embryo selection may, therefore, be considered to minimize the number of interventions while producing comparable outcomes. Whether these benefits outweigh drawbacks such as the cost for the patient, the higher workload for the IVF lab and the potential effect on the children born after prolonged culture and/or cryopreservation remains to be shown.

STUDY FUNDING/COMPETING INTEREST(S):

This study was funded by the European Society of Human Reproduction and Embryology. Illumina provided microarrays and other consumables necessary for aCGH testing of polar bodies. M.B.'s institution (UZBrussel) has received educational grants from IBSA, Ferring, Organon, Schering-Plough, Merck and Merck Belgium. M.B. has received consultancy and speakers' fees from Organon, Serono Symposia and Merck. G.G. has received personal fees and non-financial support from MSD, Ferring, Merck-Serono, Finox, TEVA, IBSA, Glycotope, Abbott and Gedeon-Richter as well as personal fees from VitroLife, NMC Healthcare, ReprodWissen, BioSilu and ZIVA. W.V., C.S., P.M.B., V.G., G.A., M.D., T.E.G., L.G., G.Ka., G.Ko., J.L., M.C.M., M.P., A.S., M.T., K.V., J.G. and K.S. declare no conflict of interest.

TRIAL REGISTRATION NUMBER:

NCT01532284.

TRIAL REGISTRATION DATE:

7 February 2012.

DATE OF FIRST PATIENT’S ENROLMENT:

25 June 2012.

PMID:
30085138
DOI:
10.1093/humrep/dey262
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center